PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PostNews: Press Release
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
PostNews: Press Release
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
PostNews: Interim Report
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
PostNews: Press Release
PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share
PHI has appointed Pareto Securities as the Company’s liquidity provider.
PostNews: Press Release
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
No Blood, No Tumor
Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.
Big Data, Fewer Cells
Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
3D Culture
Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.
Big Pharma, Big Data
Imaged-based time-lapse cytometers, as our HoloMonitor, creates huge amounts of information on how cells interact and multiply over long time periods. Combined with Big Data technology, such novel instrumentation will provide cell biologists and the pharmaceutical industry with a game changing new tool to better understand complex cellular interactions and through this hopefully cure cancer.
